|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
BRCA2 and Beyond: Unraveling Genetic Drivers of Prostate Cancer Aggressiveness
|
Hiba Khan, MD, MPH
Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations.
|
|
|
|
|
|
|
|
|
|
|
| Tumor Heterogeneity Selective Pressure – Why We Need New Targets? |
| Oliver Sartor, MD |
| As part of this online medical education program, Beyond Androgen Blockade to New Pathways and Novel Treatments in Metastatic Hormone-Sensitive Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, Oliver Sartor joins Alicia Morgans to discuss tumor heterogeneity, selective pressure and why we need new targets. |
|
|
|
|
|
|
|
|
|
|
|
| PARP Inhibitors: Targeting DNA Repair Pathways |
| Neal Shore, MD, FACS |
| In this online medical education program, Beyond Adjuvant Blockade: to New Pathways and Novel Treatments for mHSPC and mCRPC, Neal Shore joins Fred Saad to discuss PARP Inhibitors - Targeting DNA Repair Pathways. |
|
|
|
|
|
|
|
|
|
|
|
|
The Use of PARP Inhibitors in mCRPC with BRCA1/2 Alterations
|
|
Joaquin Mateo, MD, Ph.D.
|
| Alicia Morgans speaks with Joaquin Mateo about his presentation on PARP inhibitors. Dr. Mateo discusses the role of PARP inhibitors in treating metastatic castration-resistant prostate cancer with BRCA1 or BRCA2 mutations, noting the poor prognosis associated with these mutations but highlighting the effectiveness of PARP inhibitors like olaparib and rucaparib.
|
|
|
|
|
|
|
|
|
|
|
|
| Patient-Reported Outcomes in Men with mCRPC and HRR Mutations Receiving Talazoparib + Enzalutamide vs Placebo + Enzalutamide: Results from the Phase 3 TALAPRO-2 Study
|
| Andre Fay, MD, Ph.D.
|
| Andre Fay presented the phase 3 TALAPRO-2 study results, highlighting patient-reported outcomes in men with mCRPC and HRR mutations treated with talazoparib + enzalutamide versus placebo + enzalutamide. The study showed a statistically significant improvement in imaging-based progression-free survival and a longer time to definitive deterioration in global health status/quality of life and urinary symptoms for the talazoparib combination.
|
|
|
|
|
|
|
|
|
|
|
| The Best Use of PARP Inhibitors in mCRPC |
| Joaquin Mateo, MD |
| Joaquin Mateo discusses the optimal use of PARP inhibitors in mCRPC, emphasizing that BRCA-deficient mCRPC represents a distinct subset with poor prognosis but high sensitivity to PARP inhibition, as demonstrated in trials like TOPARP-B, PROFOUND, and TRITON 3. He highlights key questions including differences in efficacy between BRCA1 and BRCA2 mutations, the impact of germline versus somatic mutations, and the timing and rationale for combining PARP inhibitors with androgen receptor pathway inhibitors. |
|
|
|
|
|
| A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy (RP) in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune) |
| Rana McKay, MD |
| Rana McKay presented NePtune, a phase II trial investigating neoadjuvant PARP inhibition followed by radical prostatectomy in patients with unfavorable intermediate- or high-risk prostate cancer and BRCA1/2 gene alterations. This single-arm study aims to enroll 32 patients and evaluate the primary endpoint of achieving pathologic complete response or minimal residual disease post-surgery, as assessed by central pathology review. |
|
|
|
|
|
| Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis - Beyond the Abstract
|
| Tibor Szarvas, Péter Nyirády, Boris Hadaschik, and Tamás Fazekas
|
| The systematic review and meta-analysis presented by Tibor Szarvas and colleagues examined the efficacy of PARP inhibitors compared to platinum chemotherapy in BRCA-positive mCRPC. They found comparable efficacy between PARP inhibitors (niraparib, olaparib, talazoparib) and carboplatin in terms of PSA50 response rates and overall survival. This suggests that platinum-based therapies could be a viable treatment option for these patients.
|
|
|
|
|
|
|
|
|
|
|
